Partial replicate design & ABE for the FDA [Design Issues]

posted by nobody – 2017-03-06 15:18 (3397 d 02:19 ago) – Posting: # 17141
Views: 13,851

Les Benet at the BioInternational ’94 in Munich. You’ve been there…


Nice location, btw. ;-) (you still have the list of participants? ***glotz***)

...but even some 10 years ago (and later) from time to time this sentiment came up from Schlipsträgers...

Re. Test better than Ref: But you can't know in advance and if you have a look at some of the "companies" nowadays "developing" generics your "gut feeling"/experience from the past might be subjected to some change (as so many things nowadays...)

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
117 visitors (0 registered, 117 guests [including 14 identified bots]).
Forum time: 18:38 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5